Cash flows from operating activities | |
Net income | -69.48M |
Adjustments to reconcile net income to net cash provided by operating activities: | |
Depreciation and amortization | |
Sale of intellectual property rights | |
Stock-based compensation | 11.74M |
Amortization of premium on marketable securities | |
Undistributed (earnings) losses of joint ventures | |
(Gain) loss on disposal of long-lived assets | -41K |
Sale of contract manufacturing business | |
Loss on investment | |
Changes in operating assets and liabilities, net of acquisitions and disposals: | |
Accounts receivable | -1.8M |
Inventories | 8.57M |
Prepaid expenses and other current assets | -428K |
Accounts payable | -5.14M |
Deferred revenue | -3.29M |
Accrued warranty and retrofit costs | 290K |
Accrued compensation and benefits | -3.23M |
Accrued restructuring costs | 3.86M |
Accrued expenses and other | |
Net cash provided by operating activities | |
Cash flows from investing activities | |
Purchases of property, plant and equipment | -12.85M |
Purchases of marketable securities | -12.9M |
Sale/maturity of marketable securities | 139.39M |
Increase in restricted cash | 0 |
Proceeds from the sale of the contract manufacturing business | |
Proceeds from assets sold | |
Acquisition of RTS Life Sciences, net of cash acquired | -125.25M |
Proceeds from the sale of intellectual property rights | |
Purchase of intangible assets | |
Other | |
Net cash provided by (used in) investing activities | |
Cash flows from financing activities | |
Proceeds from issuance of common stock, net of issuance costs | |
Net cash provided by financing activities | |
Effects of exchange rate changes on cash and cash equivalents | 1.65M |
Net increase (decrease) in cash and cash equivalents | 4.36M |
Cash and cash equivalents, beginning of period | 80.72M |
Cash and cash equivalents, end of period | 85.09M |